Impact of Antibiotic Treatment on Prostate-Specific Antigen (PSA) Variability

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE4

Total Enrollment

31 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-01-31

Study Completion Date

2011-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Ciprofloxacin hydrochloride has been approved by the Food and Drug Administration (FDA) for the treatment of mild to moderate infections, including prostate infections. It has been suggested that antibiotic treatment influences PSA levels due to the fact that an increase in PSA levels may be caused by inflammation or swelling of the prostate. Antibiotics are used to treat such inflammatory conditions. However, it has not been proven that antibiotics can be used to lower PSA. This research is being done to see if treatment with the antibiotic Ciprofloxacin hydrochloride affects the Prostate-Specific Antigen (PSA) blood test. This study may also help doctors in deciding which patients need a prostate biopsy.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Randomized Trial of Ciprofloxacin Versus Observation for Men With Elevated Prostate Specific Antigen (PSA)

NCT00840294

Elevated Prostate Specific Antigen

TERMINATED PHASE3

Chronic Prostatitis Collaborative Research Network Clinical Trial- Ciprofloxacin and Tamsulosin

NCT04552431

Chronic Prostatitis With Chronic Pelvic Pain Syndrome

COMPLETED PHASE2

An Effectiveness and Safety Study for Levofloxacin in Chronic Prostatitis

NCT00402688

Prostatitis

COMPLETED PHASE3

Impact of Anti-inflammatory Medications in Patients With Elevated Serum Prostate-specific Antigen

NCT05512754

Elevated Serum PSA

RECRUITING PHASE4

Short or Long Schemes of Antibiotic Prophylaxis for Prostate Biopsy

NCT00294749

Men Who Must Undergo a Prostate Biopsy Related to Prostate Cancer Suspicion.

TERMINATED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study is directed towards men who have been referred to the Urology clinic at the Johns Hopkins Outpatient Center in Baltimore, MD. If a patient fits the eligibility criteria and signs a consent form, the patient will have his blood drawn for the first PSA measurement. The patient must return to the Johns Hopkins Outpatient Center one week later for a second PSA measurement. The patient will be randomized to receive treatment with placebo or Ciprofloxacin hydrochloride for 14 days. The patient must return to the Johns Hopkins Outpatient Center at the end of the treatment cycle for the third PSA measurement. The patient will return one week later for his biopsy and fourth PSA measurement.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Prostate Infections

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Placebo

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Placebo twice a day for 14 days

Ciprofloxacin hydrochloride

Group Type EXPERIMENTAL

Ciprofloxacin hydrochloride

Intervention Type DRUG

250 mg Ciprofloxacin hydrochloride twice a day for 14 days

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Ciprofloxacin hydrochloride

250 mg Ciprofloxacin hydrochloride twice a day for 14 days

Intervention Type DRUG

Placebo

Placebo twice a day for 14 days

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Must be a patient of Johns Hopkins Urology Outpatient Clinic
* Must have an elevated PSA (\> 2.5 ng/mL) and be selected on the basis of a serum PSA evaluation for Transrectal Ultrasound (TRUS)/biopsy
* Must be able to understand and willing to adhere to the study protocol
* Must be willing to take the antibiotic or placebo for two weeks prior to the biopsy and agree to have the biopsy regardless of the change in PSA

Exclusion Criteria

* Abnormal digital rectal examination
* Anyone currently being treated or who have been treated for any prostatic diseases (prostatitis, prostate Benign Prostatic Hyperplasia (BPH) surgery, prostate cancer) or urinary tract infection in the past
* Anyone taking medications that are likely to alter serum PSA concentration (specifically, androgen steroid hormones, antiandrogens, finasteride, Leutinizing Hormone Releasing Hormone (LHRH) analogues)
* Anyone unwilling to sign the informed consent or who are unlikely to adhere to the study protocol
* Anyone with a known allergy to fluoroquinolone antibiotics
* Anyone on blood thinning medication (Coumadin)
* Anyone taking Tizanidine
* Anyone with a history of seizures or cerebral arteriosclerosis
* Anyone who has taken an antibiotic medication within the past two weeks

Minimum Eligible Age

40 Years

Maximum Eligible Age

75 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

No